Brief: Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
03/09/2024 12:11
Sept 3 (Reuters) - Cartesian Therapeutics Inc RNAC.O :
* CARTESIAN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
FIRST-IN-HUMAN PHASE 1 TRIAL OF NEXT-GENERATION MRNA CAR-T CELL
THERAPY DESCARTES-15
* CARTESIAN THERAPEUTICS INC - DESCARTES-15 TO BE ASSESSED
IN
AUTOIMMUNE INDICATIONS FOLLOWING PHASE 1 TRIAL
Source text for Eikon: ID:nGNXbG4Qk8
Further company coverage: RNAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview